moatshark My

All holdings

Glaukos

GKOS

Source: the SEC Form 13F filings of the managers we follow, latest for Q3 2026. How we use them

Managers holding
1
In their latest 13F (Q3 2026)
See who
Value held
$673k
Combined value at quarter end
Last quarter
1 bought
0 sold or trimmed
Price at Q2 ’26 end
$139.76

Prices here are quarter-end prices implied by the 13F filings. Today’s price on Yahoo Finance

Managers holding it, by quarter

0Q4 ’23
0Q1 ’24
0Q2 ’24
0Q3 ’24
0Q4 ’24
0Q1 ’25
0Q2 ’25
0Q3 ’25
0Q4 ’25
0Q1 ’26
1Q2 ’26
0Q3 ’26
Q4 ’23: 0; Q1 ’24: 0; Q2 ’24: 0; Q3 ’24: 0; Q4 ’24: 0; Q1 ’25: 0; Q2 ’25: 0; Q3 ’25: 0; Q4 ’25: 0; Q1 ’26: 0; Q2 ’26: 1; Q3 ’26: 0

Counts the managers on this site whose 13F for that quarter includes Glaukos.

Who holds it

Each manager’s latest 13F, sorted by how much of their portfolio it is. Changes are against their previous quarter.

Managers holding Glaukos
Polen Capital Management0.0%$673k$673kNew1 qtr

Download the holders: CSV · JSON · Markdown

Directors buying and selling

Open-market trades by directors, officers and 10% holders over the last 12 months. How this works
From their Form 4 filings with the SEC. Grants, option exercises and shares sold to pay tax are left out.
Insider purchases and sales of Glaukos
Bought or soldFiling
5 Oct 2026Navratil TomasCHIEF DEVELOPMENT OFFICER▼ Sold888$163.93$146kForm 4
5 Oct 2026Navratil TomasCHIEF DEVELOPMENT OFFICER▼ Sold327$164.78$54kForm 4
5 Oct 2026Navratil TomasCHIEF DEVELOPMENT OFFICER▼ Sold312$165.60$52kForm 4
25 Sep 2026Navratil TomasCHIEF DEVELOPMENT OFFICER▼ Sold1,083$154.88$168kForm 4
25 Sep 2026Navratil TomasCHIEF DEVELOPMENT OFFICER▼ Sold229$154.24$35kForm 4
25 Sep 2026Navratil TomasCHIEF DEVELOPMENT OFFICER▼ Sold167$151.70$25kForm 4
25 Sep 2026Navratil TomasCHIEF DEVELOPMENT OFFICER▼ Sold136$152.71$21kForm 4
16 Sep 2026Navratil TomasCHIEF DEVELOPMENT OFFICER▼ Sold460$167.32$77kForm 4
16 Sep 2026Navratil TomasCHIEF DEVELOPMENT OFFICER▼ Sold345$164.60$57kForm 4
16 Sep 2026Navratil TomasCHIEF DEVELOPMENT OFFICER▼ Sold234$170.95$40kForm 4
16 Sep 2026Navratil TomasCHIEF DEVELOPMENT OFFICER▼ Sold191$166.20$32kForm 4
16 Sep 2026Navratil TomasCHIEF DEVELOPMENT OFFICER▼ Sold120$168.38$20kForm 4
16 Sep 2026Navratil TomasCHIEF DEVELOPMENT OFFICER▼ Sold103$163.20$17kForm 4
16 Sep 2026Navratil TomasCHIEF DEVELOPMENT OFFICER▼ Sold4$172.00$1kForm 4
28 Aug 2026Navratil TomasCHIEF DEVELOPMENT OFFICER▼ Sold7,643$180.25$1.4mForm 4
28 Aug 2026Navratil TomasCHIEF DEVELOPMENT OFFICER▼ Sold6,091$181.19$1.1mForm 4
28 Aug 2026Navratil TomasCHIEF DEVELOPMENT OFFICER▼ Sold10$182.50$2kForm 4
19 Aug 2026Kliman Gilbert HDirector▼ Sold2,500$190.00$475kForm 4
11 Aug 2026Gilliam Joseph EPRESIDENT & COO▼ Sold32,037$180.49$5.8mForm 4
11 Aug 2026Gilliam Joseph EPRESIDENT & COO▼ Sold27,963$178.89$5.0mForm 4

About the company

Sector
Health care · Surgical & Medical Instruments & Apparatus
Incorporated in
Delaware
Financial year ends
31 December
Shares outstanding
59m at 28 Jul 2026
SEC filings
Annual reports and other filings on EDGAR

Revenue and profit

$20.9m2013
$71.7m2015
$159m2017
$237m2019
$294m2021
$315m2023
$507m2025
2013: $20.9m; 2014: $45.6m; 2015: $71.7m; 2016: $114m; 2017: $159m; 2018: $181m; 2019: $237m; 2020: $225m; 2021: $294m; 2022: $283m; 2023: $315m; 2024: $383m; 2025: $507m
Glaukos revenue and net income by year
YearRevenueNet income
2025$507m−$188m
2024$383m−$146m
2023$315m−$135m
2022$283m−$99.2m
2021$294m−$49.6m
2020$225m−$120m
2019$237m$15.4m
2018$181m−$13.0m
2017$159m−$92k
2016$114m$4.5m
2015$71.7m−$37.2m
2014$45.6m−$12.1m
2013$20.9m−$12.6m

From the company’s XBRL financial statements filed with the SEC, for each financial year. Gaps mean the company didn’t report that figure in a standard form.